8.880EUR-0.34%Mkt Cap: 430.76M EURP/E: —Last update: 2026-05-14
Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clini…
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Valuation
P/E (Trailing)—
P/E (Forward)-11.73
PEG—
P/B-19.15
P/S6.58
EV/EBITDA-9.29
EV/Revenue7.35
EPS (TTM)-1.72
EPS (Forward)-0.73
Cash Flow & Leverage
FCF Yield-13.21%
FCF Margin-86.99%
Operating CF-26.24M EUR
CapEx (TTM)3.42M EUR
Net Debt/EBITDA-0.96
Net Debt49.59M EUR
Technical
SMA 508.602 (+3.2%)
SMA 2005.656 (+57.0%)
Beta1.08
S&P 52W Chg24.23%
Avg Vol (30d)251.58K
Avg Vol (10d)175.33K
Technical Indicators
RSI (14)56.8
MACD0.0746
MACD Signal0.0084
MACD Hist.+0.0662
BB Upper9.388 EUR
BB Middle8.545 EUR
BB Lower7.702 EUR
BB Width19.72%
ATR (14)0.4569 EUR
Vol Ratio (20d)1.10x
52W Range
3.04887% of range9.715
52W High9.715 EUR
52W Low3.048 EUR
Profitability
Gross Margin99.54%
EBITDA Margin-79.15%
Profit Margin-131.38%
Oper. Margin-179.59%
ROE381.47%
ROA-54.05%
Revenue Growth211.80%
Earnings Growth—
Balance Sheet
Debt/Equity-6.69
Current Ratio2.00
Quick Ratio1.96
Book Value/Sh-0.4490 EUR
Cash/Share2.015 EUR
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 EUR
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Ownership
Shares Out.50.09M
Float41.15M
Insiders13.22%
Institutions8.07%
Analyst Consensus
Rating1.0 (Strong Buy)
Target (Mean)14.00 EUR
Target Range11.00 EUR – 15.00 EUR
# Analysts4
Company
Market Cap430.76M EUR
Enterprise Value481.13M EUR
Revenue (TTM)65.43M EUR
Gross Profit65.13M EUR
Net Income (TTM)-85.97M EUR
Revenue/Share1.309 EUR
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees—
Last Price8.880 EUR
CountryFR
SectorHealthcare
IndustryBiotechnology
ISIN—